Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Descending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
83090-0009-01 83090-0009 Arsenic trioxide ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 9, 2023 In Use
83090-0009-10 83090-0009 Arsenic trioxide ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 9, 2023 In Use
83090-0010-01 83090-0010 Arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 9, 2023 In Use
83090-0010-10 83090-0010 Arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 9, 2023 In Use
83634-0202-61 83634-0202 Melphalan hydrochloride Melphalan Hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 18, 2023 In Use
83774-0100-60 83774-0100 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 27, 2024 In Use
83774-0101-12 83774-0101 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 27, 2024 In Use
00003-4040-12 00003-4040 Repotrectinib Augtyro 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Dec. 5, 2023 In Use
00003-4040-60 00003-4040 Repotrectinib Augtyro 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Dec. 5, 2023 In Use
00310-9500-01 00310-9500 Capivasertib TRUQAP 160.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov. 16, 2023 In Use
00310-9501-01 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov. 16, 2023 In Use
63020-0210-21 63020-0210 Fruquintinib Fruzaqla 1.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 8, 2023 In Use
63020-0225-21 63020-0225 Fruquintinib Fruzaqla 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 8, 2023 In Use
16729-0092-03 16729-0092 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 28, 2011 In Use
00013-2586-91 00013-2586 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 17, 1997 In Use
00013-2586-10 00013-2586 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous March 11, 2024 In Use
00013-2596-91 00013-2596 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 17, 1997 In Use
00013-2596-20 00013-2596 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous March 11, 2024 In Use
00078-0649-30 00078-0649 Imatinib Mesylate Gleevec 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 23, 2014 In Use
00078-0649-13 00078-0649 Imatinib Mesylate Gleevec 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 1, 2024 In Use
25021-0258-61 25021-0258 Melphalan Hydrochloride Melphalan Hydrochloride 50.0 mg/10ml Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 1, 2024 In Use
16729-0117-11 16729-0117 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 1, 2011 In Use
16729-0118-38 16729-0118 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 2.0 g/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 31, 2011 In Use
43826-0066-04 43826-0066 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral Dec. 1, 2022 In Use
66758-0950-02 66758-0950 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 22, 2015 In Use

Found 10,000 results in 8 milliseconds — Export these results